Lantidra Market Report 2026

Lantidra Market Overview

• The Lantidra market growth in the historic period has been driven by advances in pancreatic cell biology, unmet needs in type 1 diabetes management • Market expansion is supported by expansion of curative diabetes treatment research, increasing adoption of cell therapies in endocrinology • Growth Driver: Rising Prevalence Of Type-1 Diabetes Driving The Market Growth • Market Trend: Advancements In Allogeneic Pancreatic Islet Cellular Therapy For Type 1 Diabetes Management • North America was the largest region in 2025.

What Is Covered Under Lantidra Market?

Lantidra is a cell-based therapy designed to treat type 1 diabetes by using genetically modified donor pancreas cells to restore natural insulin production. It reduces or eliminates the need for external insulin injections, improving blood sugar control. Its goal is to replace the pancreas function, offering a more sustainable option and enhancing the quality of life for insulin-dependent patients. The main types of lantidra formulation are injectable formulation (subcutaneous) and pre-filled syringes, or auto-injectors. Injectable formulation (subcutaneous) delivers medication under the skin for gradual absorption, offering controlled release and easy self-administration for chronic conditions. It is applicable in various indications, such as the delay of clinical type 1 diabetes, prevention of type 1 diabetes, and treatment of newly diagnosed type 1 diabetes for several patient demographics, including pediatric patients, adult patients, and geriatric patients. It is distributed through various distribution channels, such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and used by several end users, including hospitals, specialty clinics, home healthcare providers, and research institutions.

What Is The Lantidra Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of curative diabetes treatment research, increasing adoption of cell therapies in endocrinology, advancements in immune protection strategies, rising focus on long-term glucose control solutions, supportive regulatory frameworks for cell therapies. Major trends in the forecast period include increasing development of cell-based diabetes therapies, expansion of regenerative medicine approaches, growing focus on insulin independence solutions, rising integration of gene-modified cell platforms, enhanced patient quality of life outcomes.

What Are The Drivers Of The Lantidra Market?

The rising prevalence of type-1 diabetes is expected to propel the growth of the lantidra market going forward. Type-1 diabetes refers to a chronic condition where the immune system attacks the insulin-producing cells in the pancreas, leading to a lack of insulin and requiring lifelong insulin therapy for blood sugar regulation. The prevalence of Type 1 diabetes is attributed to factors such as genetic predisposition, environmental triggers such as viral infections, immune system malfunctions, and improved diagnostic capabilities. Lantidra involves transplanting insulin-producing cells from donated pancreas to restore natural insulin production in type 1 diabetes patients. This treatment improves blood sugar control, reduces insulin dependence, and may lower the risk of complications. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%. Therefore, the rising prevalence of type-1 diabetes drives the lantidra industry growth. The rising healthcare spending is significantly driving the growth of the lantidra market going forward. Healthcare spending encompasses the overall financial outlay for healthcare services, covering medical treatments, hospital services, pharmaceuticals, and healthcare infrastructure. Healthcare spending rises due to factors such as an aging population, increasing prevalence of chronic diseases, advancements in medical technology, and greater demand for healthcare services. Rising healthcare spending boosts investment in advanced treatments such as Lantidra, which offers improved outcomes and long-term savings. This funding enhances access to innovative therapies across broader regions and patient groups. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based Institute for Health Information, total health spending in Canada is projected to reach $344 billion in 2023, equating to $8,740 per person. This marks a 2.8% increase compared to the 2022. Therefore, the rising healthcare spending is driving the lantidra industry growth.

Key Players In The Global Lantidra Market

Major companies operating in the lantidra market are CellTrans Inc.

Global Lantidra Market Trends and Insights

The key trend of the lantidra market is developing advanced therapies such as allogeneic (donor) pancreatic islet cellular therapy to improve the management of type 1 diabetes by reducing the dependence on insulin injections. Allogeneic (donor) pancreatic islet cellular therapy involves transplanting insulin-producing islet cells from a healthy donor into a recipient. This therapy helps restore insulin production in individuals with type 1 diabetes who have lost this function due to damaged pancreatic cells. For instance, in June 2023, CellTrans Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Lantidra to provide insulin-producing beta cells, offering a potential solution for patients with severe hypoglycemia and insulin dependency. It is administered via a single infusion into the liver's portal vein, and Lantidra may reduce or eliminate the need for insulin injections in some patients. The therapy is approved with patient-directed labeling, highlighting both benefits and risks, including the need for immunosuppressive medications to maintain islet cell function.

What Defines the Lantidra Market?

The lantidra market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lantidra Market Report 2026?

The lantidra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lantidra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.